视网膜色素变性中黄斑新生血管的临床特征与治疗结局
该研究回顾性分析了韩国三家三级医院2730例视网膜色素变性(RP)患者的病历,发现黄斑新生血管(MNV)患病率为0.26%(7例),中位发病年龄59岁。所有患者接受玻璃体腔注射抗血管内皮生长因子(anti-VEGF)治疗,中位注射次数5次,治疗后视力和解剖结构均改善,5例随访超过3年的患者无疾病进展或视野进一步缩窄。
要点
- 在2730例RP患者中,MNV患病率为0.26%(7例),中位发病年龄59岁。
- 所有患者接受玻璃体腔注射anti-VEGF治疗,中位注射次数5次,治疗后视力和解剖结构均改善。
- 6例患者在1至6次注射后MNV稳定无复发,1例需重复治疗;5例随访超过3年者无疾病进展或视野进一步缩窄。
核心结论
- MNV是RP患者的罕见并发症,发病年龄较年龄相关性黄斑变性患者更年轻。
- 玻璃体腔注射anti-VEGF治疗RP相关MNV可有效保留视力,且不加速RP的临床病程。
研究设计与样本
- 回顾性研究,纳入韩国三家三级医院诊断为RP的患者2730例,诊断依据症状、眼底表现和视网膜电图。
- 所有患者接受玻璃体腔注射anti-VEGF治疗。
主要发现
- 2730例RP患者中7例发现MNV,患病率为0.26%。
- MNV发病中位年龄为59岁(范围52-75岁)。
- anti-VEGF注射中位次数为5次(范围1-43次)。
- 治疗后所有患者均观察到视力和解剖结构改善。
- 6例患者在1至6次anti-VEGF注射后MNV稳定无复发,1例需重复治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the clinical features, prevalence, and treatment outcomes of macular neovascularization (MNV) in patients with retinitis pigmentosa (RP). METHODS: The authors retrospectively reviewed the medical records of patients diagnosed with RP at three tertiary hospitals in South Korea. The diagnosis of RP was based on symptoms, funduscopic findings, and electroretinography. All patients were treated with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) injection. RESULTS: Among the 2,730 patients with RP, MNV was identified in 7 patients (prevalence: 0.26%). The median age at MNV onset was 59 years (range: 52-75 years). The median number of anti-VEGF injections was 5 (range: 1-43). After treatment, visual and anatomical improvements were observed in all patients. In six patients, MNV stabilized without recurrence after one to six anti-VEGF injections, whereas one patient needed repeated treatment. The 5 patients with a follow-up period more than 3 years exhibited no signs of disease progression or further constriction of the visual field. CONCLUSION: The MNV is a rare complication in patients with RP, occurring at a younger age than in those with age-related macular degeneration. Intravitreal anti-VEGF injections for the treatment of RP-related MNV were effective in preserving vision without accelerating the clinical course of RP.
引用
- Lee HJ, Lee EK, Sagong M, et al. CLINICAL CHARACTERIZATION AND TREATMENT OUTCOMES OF MACULAR NEOVASCULARIZATION IN RETINITIS PIGMENTOSA. Retina. 2025. PMID: 40456126. doi:10.1097/IAE.0000000000004541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。